nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—CBR1—Doxorubicin—thyroid cancer	0.277	0.371	CbGbCtD
Haloperidol—UGT1A9—Sorafenib—thyroid cancer	0.115	0.154	CbGbCtD
Haloperidol—HTR2B—Sorafenib—thyroid cancer	0.0902	0.121	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.0383	0.0513	CbGbCtD
Haloperidol—CYP3A7—Sorafenib—thyroid cancer	0.0383	0.0513	CbGbCtD
Haloperidol—CYP3A5—Sorafenib—thyroid cancer	0.0287	0.0385	CbGbCtD
Haloperidol—CYP2C19—Sorafenib—thyroid cancer	0.0232	0.031	CbGbCtD
Haloperidol—CYP1A2—Sorafenib—thyroid cancer	0.0214	0.0286	CbGbCtD
Haloperidol—CYP2C9—Sorafenib—thyroid cancer	0.0193	0.0258	CbGbCtD
Haloperidol—ABCB1—Sorafenib—thyroid cancer	0.0187	0.025	CbGbCtD
Haloperidol—CYP3A4—Vandetanib—thyroid cancer	0.0186	0.0249	CbGbCtD
Haloperidol—CYP2D6—Sorafenib—thyroid cancer	0.0176	0.0236	CbGbCtD
Haloperidol—ABCB1—Doxorubicin—thyroid cancer	0.0113	0.0152	CbGbCtD
Haloperidol—CYP3A4—Sorafenib—thyroid cancer	0.0112	0.015	CbGbCtD
Haloperidol—CYP2D6—Doxorubicin—thyroid cancer	0.0107	0.0143	CbGbCtD
Haloperidol—CYP3A4—Doxorubicin—thyroid cancer	0.00679	0.0091	CbGbCtD
Haloperidol—H1F0—neck—thyroid cancer	0.00166	0.0656	CbGeAlD
Haloperidol—CBR1—saliva-secreting gland—thyroid cancer	0.00158	0.0624	CbGeAlD
Haloperidol—H1F0—saliva-secreting gland—thyroid cancer	0.00129	0.0512	CbGeAlD
Haloperidol—CBR1—trachea—thyroid cancer	0.00122	0.0482	CbGeAlD
Haloperidol—GRIN2B—head—thyroid cancer	0.00115	0.0456	CbGeAlD
Haloperidol—H1F0—trachea—thyroid cancer	0.000998	0.0395	CbGeAlD
Haloperidol—Body temperature decreased—Epirubicin—thyroid cancer	0.000972	0.00647	CcSEcCtD
Haloperidol—Hypothermia—Epirubicin—thyroid cancer	0.000972	0.00647	CcSEcCtD
Haloperidol—Alopecia—Vandetanib—thyroid cancer	0.00097	0.00646	CcSEcCtD
Haloperidol—Breast disorder—Sorafenib—thyroid cancer	0.000967	0.00644	CcSEcCtD
Haloperidol—DRD3—head—thyroid cancer	0.000966	0.0382	CbGeAlD
Haloperidol—CBR1—thyroid gland—thyroid cancer	0.000964	0.0381	CbGeAlD
Haloperidol—Mental disorder—Vandetanib—thyroid cancer	0.000962	0.0064	CcSEcCtD
Haloperidol—Malnutrition—Vandetanib—thyroid cancer	0.000956	0.00636	CcSEcCtD
Haloperidol—SIGMAR1—saliva-secreting gland—thyroid cancer	0.000935	0.037	CbGeAlD
Haloperidol—Dysphagia—Sorafenib—thyroid cancer	0.000925	0.00616	CcSEcCtD
Haloperidol—Muscle spasms—Vandetanib—thyroid cancer	0.000919	0.00612	CcSEcCtD
Haloperidol—Vision blurred—Vandetanib—thyroid cancer	0.000901	0.006	CcSEcCtD
Haloperidol—Hypothermia—Doxorubicin—thyroid cancer	0.0009	0.00599	CcSEcCtD
Haloperidol—Body temperature decreased—Doxorubicin—thyroid cancer	0.0009	0.00599	CcSEcCtD
Haloperidol—Tremor—Vandetanib—thyroid cancer	0.000895	0.00596	CcSEcCtD
Haloperidol—Neutropenia—Sorafenib—thyroid cancer	0.000865	0.00576	CcSEcCtD
Haloperidol—CBR1—head—thyroid cancer	0.000855	0.0338	CbGeAlD
Haloperidol—Erectile dysfunction—Sorafenib—thyroid cancer	0.000852	0.00567	CcSEcCtD
Haloperidol—Weight decreased—Sorafenib—thyroid cancer	0.000837	0.00557	CcSEcCtD
Haloperidol—Convulsion—Vandetanib—thyroid cancer	0.000828	0.00551	CcSEcCtD
Haloperidol—Hypertension—Vandetanib—thyroid cancer	0.000825	0.00549	CcSEcCtD
Haloperidol—Anxiety—Vandetanib—thyroid cancer	0.000811	0.0054	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.000808	0.00538	CcSEcCtD
Haloperidol—Hypokinesia—Epirubicin—thyroid cancer	0.000807	0.00537	CcSEcCtD
Haloperidol—Jaundice—Sorafenib—thyroid cancer	0.000804	0.00535	CcSEcCtD
Haloperidol—Dry mouth—Vandetanib—thyroid cancer	0.000796	0.0053	CcSEcCtD
Haloperidol—H1F0—thyroid gland—thyroid cancer	0.00079	0.0312	CbGeAlD
Haloperidol—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00078	0.00519	CcSEcCtD
Haloperidol—Oedema—Vandetanib—thyroid cancer	0.00078	0.00519	CcSEcCtD
Haloperidol—Nervous system disorder—Vandetanib—thyroid cancer	0.000765	0.00509	CcSEcCtD
Haloperidol—Thrombocytopenia—Vandetanib—thyroid cancer	0.000764	0.00508	CcSEcCtD
Haloperidol—Nystagmus—Epirubicin—thyroid cancer	0.000763	0.00508	CcSEcCtD
Haloperidol—Skin disorder—Vandetanib—thyroid cancer	0.000758	0.00504	CcSEcCtD
Haloperidol—Hypokinesia—Doxorubicin—thyroid cancer	0.000747	0.00497	CcSEcCtD
Haloperidol—Ventricular arrhythmia—Epirubicin—thyroid cancer	0.000736	0.0049	CcSEcCtD
Haloperidol—Urinary tract disorder—Sorafenib—thyroid cancer	0.000731	0.00487	CcSEcCtD
Haloperidol—Connective tissue disorder—Sorafenib—thyroid cancer	0.000728	0.00484	CcSEcCtD
Haloperidol—Urethral disorder—Sorafenib—thyroid cancer	0.000726	0.00483	CcSEcCtD
Haloperidol—SIGMAR1—trachea—thyroid cancer	0.000721	0.0285	CbGeAlD
Haloperidol—Nystagmus—Doxorubicin—thyroid cancer	0.000706	0.0047	CcSEcCtD
Haloperidol—Insomnia—Vandetanib—thyroid cancer	0.000706	0.0047	CcSEcCtD
Haloperidol—H1F0—head—thyroid cancer	0.000701	0.0277	CbGeAlD
Haloperidol—Dyspnoea—Vandetanib—thyroid cancer	0.000695	0.00463	CcSEcCtD
Haloperidol—DRD1—head—thyroid cancer	0.000692	0.0274	CbGeAlD
Haloperidol—Cardiac disorder—Sorafenib—thyroid cancer	0.000687	0.00458	CcSEcCtD
Haloperidol—Dyspepsia—Vandetanib—thyroid cancer	0.000687	0.00457	CcSEcCtD
Haloperidol—Ventricular arrhythmia—Doxorubicin—thyroid cancer	0.000681	0.00454	CcSEcCtD
Haloperidol—Decreased appetite—Vandetanib—thyroid cancer	0.000678	0.00451	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000673	0.00448	CcSEcCtD
Haloperidol—Angiopathy—Sorafenib—thyroid cancer	0.000672	0.00447	CcSEcCtD
Haloperidol—Immune system disorder—Sorafenib—thyroid cancer	0.000669	0.00445	CcSEcCtD
Haloperidol—Mediastinal disorder—Sorafenib—thyroid cancer	0.000667	0.00444	CcSEcCtD
Haloperidol—Constipation—Vandetanib—thyroid cancer	0.000667	0.00444	CcSEcCtD
Haloperidol—Alopecia—Sorafenib—thyroid cancer	0.000654	0.00436	CcSEcCtD
Haloperidol—Mental disorder—Sorafenib—thyroid cancer	0.000649	0.00432	CcSEcCtD
Haloperidol—Malnutrition—Sorafenib—thyroid cancer	0.000645	0.00429	CcSEcCtD
Haloperidol—HTR2A—neck—thyroid cancer	0.000638	0.0252	CbGeAlD
Haloperidol—Breast pain—Epirubicin—thyroid cancer	0.000625	0.00416	CcSEcCtD
Haloperidol—Amenorrhoea—Epirubicin—thyroid cancer	0.00062	0.00413	CcSEcCtD
Haloperidol—Muscle spasms—Sorafenib—thyroid cancer	0.00062	0.00413	CcSEcCtD
Haloperidol—Body temperature increased—Vandetanib—thyroid cancer	0.000617	0.0041	CcSEcCtD
Haloperidol—CBR1—lymph node—thyroid cancer	0.000599	0.0237	CbGeAlD
Haloperidol—Anaemia—Sorafenib—thyroid cancer	0.000596	0.00397	CcSEcCtD
Haloperidol—Dyskinesia—Epirubicin—thyroid cancer	0.00058	0.00386	CcSEcCtD
Haloperidol—Breast pain—Doxorubicin—thyroid cancer	0.000578	0.00385	CcSEcCtD
Haloperidol—Leukopenia—Sorafenib—thyroid cancer	0.000577	0.00384	CcSEcCtD
Haloperidol—Amenorrhoea—Doxorubicin—thyroid cancer	0.000574	0.00382	CcSEcCtD
Haloperidol—SIGMAR1—thyroid gland—thyroid cancer	0.00057	0.0226	CbGeAlD
Haloperidol—HTR2B—thyroid gland—thyroid cancer	0.000569	0.0225	CbGeAlD
Haloperidol—HTR1B—head—thyroid cancer	0.000561	0.0222	CbGeAlD
Haloperidol—Gait disturbance—Epirubicin—thyroid cancer	0.000558	0.00372	CcSEcCtD
Haloperidol—Hypertension—Sorafenib—thyroid cancer	0.000557	0.00371	CcSEcCtD
Haloperidol—Pruritus—Vandetanib—thyroid cancer	0.000552	0.00367	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000545	0.00363	CcSEcCtD
Haloperidol—Ventricular tachycardia—Epirubicin—thyroid cancer	0.000545	0.00363	CcSEcCtD
Haloperidol—HTR1D—head—thyroid cancer	0.000543	0.0215	CbGeAlD
Haloperidol—Injection site reaction—Epirubicin—thyroid cancer	0.000542	0.00361	CcSEcCtD
Haloperidol—Dry mouth—Sorafenib—thyroid cancer	0.000537	0.00357	CcSEcCtD
Haloperidol—Dyskinesia—Doxorubicin—thyroid cancer	0.000537	0.00357	CcSEcCtD
Haloperidol—Diarrhoea—Vandetanib—thyroid cancer	0.000534	0.00355	CcSEcCtD
Haloperidol—Salivary hypersecretion—Epirubicin—thyroid cancer	0.000529	0.00352	CcSEcCtD
Haloperidol—Anaphylactic shock—Sorafenib—thyroid cancer	0.000526	0.0035	CcSEcCtD
Haloperidol—Gait disturbance—Doxorubicin—thyroid cancer	0.000517	0.00344	CcSEcCtD
Haloperidol—Nervous system disorder—Sorafenib—thyroid cancer	0.000516	0.00343	CcSEcCtD
Haloperidol—Dizziness—Vandetanib—thyroid cancer	0.000516	0.00343	CcSEcCtD
Haloperidol—Thrombocytopenia—Sorafenib—thyroid cancer	0.000515	0.00343	CcSEcCtD
Haloperidol—Skin disorder—Sorafenib—thyroid cancer	0.000511	0.0034	CcSEcCtD
Haloperidol—HTR2B—head—thyroid cancer	0.000505	0.02	CbGeAlD
Haloperidol—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.000504	0.00336	CcSEcCtD
Haloperidol—Anorexia—Sorafenib—thyroid cancer	0.000502	0.00334	CcSEcCtD
Haloperidol—Injection site reaction—Doxorubicin—thyroid cancer	0.000501	0.00334	CcSEcCtD
Haloperidol—Vomiting—Vandetanib—thyroid cancer	0.000496	0.0033	CcSEcCtD
Haloperidol—Rash—Vandetanib—thyroid cancer	0.000492	0.00327	CcSEcCtD
Haloperidol—Dermatitis—Vandetanib—thyroid cancer	0.000491	0.00327	CcSEcCtD
Haloperidol—H1F0—lymph node—thyroid cancer	0.000491	0.0194	CbGeAlD
Haloperidol—Salivary hypersecretion—Doxorubicin—thyroid cancer	0.00049	0.00326	CcSEcCtD
Haloperidol—Headache—Vandetanib—thyroid cancer	0.000489	0.00325	CcSEcCtD
Haloperidol—CYP1A1—trachea—thyroid cancer	0.000485	0.0192	CbGeAlD
Haloperidol—Hypertonia—Epirubicin—thyroid cancer	0.000478	0.00318	CcSEcCtD
Haloperidol—Dyspnoea—Sorafenib—thyroid cancer	0.000469	0.00312	CcSEcCtD
Haloperidol—Nausea—Vandetanib—thyroid cancer	0.000463	0.00308	CcSEcCtD
Haloperidol—Dyspepsia—Sorafenib—thyroid cancer	0.000463	0.00308	CcSEcCtD
Haloperidol—HRH1—trachea—thyroid cancer	0.00046	0.0182	CbGeAlD
Haloperidol—Decreased appetite—Sorafenib—thyroid cancer	0.000457	0.00304	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000454	0.00302	CcSEcCtD
Haloperidol—Hepatic function abnormal—Epirubicin—thyroid cancer	0.000453	0.00301	CcSEcCtD
Haloperidol—Photosensitivity—Epirubicin—thyroid cancer	0.000451	0.003	CcSEcCtD
Haloperidol—Constipation—Sorafenib—thyroid cancer	0.00045	0.003	CcSEcCtD
Haloperidol—Hypertonia—Doxorubicin—thyroid cancer	0.000442	0.00294	CcSEcCtD
Haloperidol—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.000419	0.00279	CcSEcCtD
Haloperidol—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.000419	0.00279	CcSEcCtD
Haloperidol—Urticaria—Sorafenib—thyroid cancer	0.000418	0.00278	CcSEcCtD
Haloperidol—Photosensitivity—Doxorubicin—thyroid cancer	0.000417	0.00278	CcSEcCtD
Haloperidol—Body temperature increased—Sorafenib—thyroid cancer	0.000416	0.00277	CcSEcCtD
Haloperidol—DRD2—head—thyroid cancer	0.000409	0.0162	CbGeAlD
Haloperidol—Hypoglycaemia—Epirubicin—thyroid cancer	0.000405	0.0027	CcSEcCtD
Haloperidol—Lethargy—Epirubicin—thyroid cancer	0.000404	0.00269	CcSEcCtD
Haloperidol—KCNH2—head—thyroid cancer	0.000403	0.0159	CbGeAlD
Haloperidol—Hyponatraemia—Epirubicin—thyroid cancer	0.000397	0.00264	CcSEcCtD
Haloperidol—CYP1A2—thyroid gland—thyroid cancer	0.000389	0.0154	CbGeAlD
Haloperidol—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.000388	0.00258	CcSEcCtD
Haloperidol—Hypersensitivity—Sorafenib—thyroid cancer	0.000388	0.00258	CcSEcCtD
Haloperidol—HTR2A—trachea—thyroid cancer	0.000384	0.0152	CbGeAlD
Haloperidol—CYP1A1—thyroid gland—thyroid cancer	0.000383	0.0152	CbGeAlD
Haloperidol—Face oedema—Epirubicin—thyroid cancer	0.000382	0.00254	CcSEcCtD
Haloperidol—Cardiac arrest—Epirubicin—thyroid cancer	0.000376	0.0025	CcSEcCtD
Haloperidol—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000375	0.0025	CcSEcCtD
Haloperidol—Lethargy—Doxorubicin—thyroid cancer	0.000374	0.00249	CcSEcCtD
Haloperidol—Pruritus—Sorafenib—thyroid cancer	0.000372	0.00248	CcSEcCtD
Haloperidol—Hyponatraemia—Doxorubicin—thyroid cancer	0.000368	0.00245	CcSEcCtD
Haloperidol—Liver function test abnormal—Epirubicin—thyroid cancer	0.000365	0.00243	CcSEcCtD
Haloperidol—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000361	0.00241	CcSEcCtD
Haloperidol—Diarrhoea—Sorafenib—thyroid cancer	0.00036	0.0024	CcSEcCtD
Haloperidol—Breast disorder—Epirubicin—thyroid cancer	0.000358	0.00238	CcSEcCtD
Haloperidol—SIGMAR1—lymph node—thyroid cancer	0.000354	0.014	CbGeAlD
Haloperidol—HTR2B—lymph node—thyroid cancer	0.000354	0.014	CbGeAlD
Haloperidol—Face oedema—Doxorubicin—thyroid cancer	0.000353	0.00235	CcSEcCtD
Haloperidol—Cardiac arrest—Doxorubicin—thyroid cancer	0.000348	0.00232	CcSEcCtD
Haloperidol—Dizziness—Sorafenib—thyroid cancer	0.000348	0.00232	CcSEcCtD
Haloperidol—Dysphagia—Epirubicin—thyroid cancer	0.000342	0.00228	CcSEcCtD
Haloperidol—CYP1A1—head—thyroid cancer	0.00034	0.0134	CbGeAlD
Haloperidol—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000338	0.00225	CcSEcCtD
Haloperidol—Vomiting—Sorafenib—thyroid cancer	0.000335	0.00223	CcSEcCtD
Haloperidol—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000334	0.00223	CcSEcCtD
Haloperidol—Rash—Sorafenib—thyroid cancer	0.000332	0.00221	CcSEcCtD
Haloperidol—Dermatitis—Sorafenib—thyroid cancer	0.000331	0.00221	CcSEcCtD
Haloperidol—Breast disorder—Doxorubicin—thyroid cancer	0.000331	0.0022	CcSEcCtD
Haloperidol—Headache—Sorafenib—thyroid cancer	0.00033	0.00219	CcSEcCtD
Haloperidol—Pancytopenia—Epirubicin—thyroid cancer	0.000325	0.00216	CcSEcCtD
Haloperidol—HRH1—head—thyroid cancer	0.000323	0.0128	CbGeAlD
Haloperidol—Neutropenia—Epirubicin—thyroid cancer	0.00032	0.00213	CcSEcCtD
Haloperidol—Dysphagia—Doxorubicin—thyroid cancer	0.000316	0.00211	CcSEcCtD
Haloperidol—Nausea—Sorafenib—thyroid cancer	0.000313	0.00208	CcSEcCtD
Haloperidol—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000312	0.00208	CcSEcCtD
Haloperidol—Weight increased—Epirubicin—thyroid cancer	0.000311	0.00207	CcSEcCtD
Haloperidol—Weight decreased—Epirubicin—thyroid cancer	0.000309	0.00206	CcSEcCtD
Haloperidol—Hyperglycaemia—Epirubicin—thyroid cancer	0.000308	0.00205	CcSEcCtD
Haloperidol—Drowsiness—Epirubicin—thyroid cancer	0.000305	0.00203	CcSEcCtD
Haloperidol—Pancytopenia—Doxorubicin—thyroid cancer	0.0003	0.002	CcSEcCtD
Haloperidol—Jaundice—Epirubicin—thyroid cancer	0.000297	0.00198	CcSEcCtD
Haloperidol—Neutropenia—Doxorubicin—thyroid cancer	0.000296	0.00197	CcSEcCtD
Haloperidol—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000289	0.00192	CcSEcCtD
Haloperidol—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000288	0.00192	CcSEcCtD
Haloperidol—Weight increased—Doxorubicin—thyroid cancer	0.000288	0.00192	CcSEcCtD
Haloperidol—Weight decreased—Doxorubicin—thyroid cancer	0.000286	0.00191	CcSEcCtD
Haloperidol—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000285	0.0019	CcSEcCtD
Haloperidol—Agranulocytosis—Epirubicin—thyroid cancer	0.000285	0.00189	CcSEcCtD
Haloperidol—Drowsiness—Doxorubicin—thyroid cancer	0.000282	0.00188	CcSEcCtD
Haloperidol—KCNH2—lymph node—thyroid cancer	0.000282	0.0111	CbGeAlD
Haloperidol—Jaundice—Doxorubicin—thyroid cancer	0.000275	0.00183	CcSEcCtD
Haloperidol—Hepatitis—Epirubicin—thyroid cancer	0.000274	0.00182	CcSEcCtD
Haloperidol—Urinary tract disorder—Epirubicin—thyroid cancer	0.00027	0.0018	CcSEcCtD
Haloperidol—HTR2A—head—thyroid cancer	0.00027	0.0107	CbGeAlD
Haloperidol—Connective tissue disorder—Epirubicin—thyroid cancer	0.000269	0.00179	CcSEcCtD
Haloperidol—Urethral disorder—Epirubicin—thyroid cancer	0.000268	0.00179	CcSEcCtD
Haloperidol—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000267	0.00178	CcSEcCtD
Haloperidol—Visual impairment—Epirubicin—thyroid cancer	0.000264	0.00176	CcSEcCtD
Haloperidol—Agranulocytosis—Doxorubicin—thyroid cancer	0.000263	0.00175	CcSEcCtD
Haloperidol—Eye disorder—Epirubicin—thyroid cancer	0.000256	0.0017	CcSEcCtD
Haloperidol—Cardiac disorder—Epirubicin—thyroid cancer	0.000254	0.00169	CcSEcCtD
Haloperidol—Hepatitis—Doxorubicin—thyroid cancer	0.000253	0.00169	CcSEcCtD
Haloperidol—ABCB1—trachea—thyroid cancer	0.000252	0.00995	CbGeAlD
Haloperidol—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00025	0.00166	CcSEcCtD
Haloperidol—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000249	0.00166	CcSEcCtD
Haloperidol—Angiopathy—Epirubicin—thyroid cancer	0.000248	0.00165	CcSEcCtD
Haloperidol—Urethral disorder—Doxorubicin—thyroid cancer	0.000248	0.00165	CcSEcCtD
Haloperidol—Immune system disorder—Epirubicin—thyroid cancer	0.000247	0.00165	CcSEcCtD
Haloperidol—Mediastinal disorder—Epirubicin—thyroid cancer	0.000247	0.00164	CcSEcCtD
Haloperidol—CYP2D6—head—thyroid cancer	0.000246	0.00971	CbGeAlD
Haloperidol—Visual impairment—Doxorubicin—thyroid cancer	0.000244	0.00162	CcSEcCtD
Haloperidol—Alopecia—Epirubicin—thyroid cancer	0.000242	0.00161	CcSEcCtD
Haloperidol—Mental disorder—Epirubicin—thyroid cancer	0.00024	0.0016	CcSEcCtD
Haloperidol—Malnutrition—Epirubicin—thyroid cancer	0.000238	0.00159	CcSEcCtD
Haloperidol—CYP1A1—lymph node—thyroid cancer	0.000238	0.00942	CbGeAlD
Haloperidol—Eye disorder—Doxorubicin—thyroid cancer	0.000237	0.00158	CcSEcCtD
Haloperidol—Cardiac disorder—Doxorubicin—thyroid cancer	0.000235	0.00156	CcSEcCtD
Haloperidol—Angiopathy—Doxorubicin—thyroid cancer	0.00023	0.00153	CcSEcCtD
Haloperidol—Muscle spasms—Epirubicin—thyroid cancer	0.000229	0.00152	CcSEcCtD
Haloperidol—Immune system disorder—Doxorubicin—thyroid cancer	0.000229	0.00152	CcSEcCtD
Haloperidol—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000228	0.00152	CcSEcCtD
Haloperidol—HRH1—lymph node—thyroid cancer	0.000226	0.00894	CbGeAlD
Haloperidol—Vision blurred—Epirubicin—thyroid cancer	0.000225	0.00149	CcSEcCtD
Haloperidol—Alopecia—Doxorubicin—thyroid cancer	0.000224	0.00149	CcSEcCtD
Haloperidol—Mental disorder—Doxorubicin—thyroid cancer	0.000222	0.00148	CcSEcCtD
Haloperidol—Malnutrition—Doxorubicin—thyroid cancer	0.00022	0.00147	CcSEcCtD
Haloperidol—Anaemia—Epirubicin—thyroid cancer	0.00022	0.00147	CcSEcCtD
Haloperidol—Agitation—Epirubicin—thyroid cancer	0.000219	0.00146	CcSEcCtD
Haloperidol—Vertigo—Epirubicin—thyroid cancer	0.000214	0.00142	CcSEcCtD
Haloperidol—Leukopenia—Epirubicin—thyroid cancer	0.000213	0.00142	CcSEcCtD
Haloperidol—Muscle spasms—Doxorubicin—thyroid cancer	0.000212	0.00141	CcSEcCtD
Haloperidol—Vision blurred—Doxorubicin—thyroid cancer	0.000208	0.00138	CcSEcCtD
Haloperidol—Convulsion—Epirubicin—thyroid cancer	0.000206	0.00137	CcSEcCtD
Haloperidol—Hypertension—Epirubicin—thyroid cancer	0.000206	0.00137	CcSEcCtD
Haloperidol—Anaemia—Doxorubicin—thyroid cancer	0.000204	0.00136	CcSEcCtD
Haloperidol—Agitation—Doxorubicin—thyroid cancer	0.000203	0.00135	CcSEcCtD
Haloperidol—Anxiety—Epirubicin—thyroid cancer	0.000202	0.00135	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000201	0.00134	CcSEcCtD
Haloperidol—ABCB1—thyroid gland—thyroid cancer	0.000199	0.00787	CbGeAlD
Haloperidol—Dry mouth—Epirubicin—thyroid cancer	0.000198	0.00132	CcSEcCtD
Haloperidol—Vertigo—Doxorubicin—thyroid cancer	0.000198	0.00132	CcSEcCtD
Haloperidol—Leukopenia—Doxorubicin—thyroid cancer	0.000197	0.00131	CcSEcCtD
Haloperidol—Confusional state—Epirubicin—thyroid cancer	0.000196	0.00131	CcSEcCtD
Haloperidol—Oedema—Epirubicin—thyroid cancer	0.000194	0.00129	CcSEcCtD
Haloperidol—Anaphylactic shock—Epirubicin—thyroid cancer	0.000194	0.00129	CcSEcCtD
Haloperidol—Convulsion—Doxorubicin—thyroid cancer	0.000191	0.00127	CcSEcCtD
Haloperidol—Nervous system disorder—Epirubicin—thyroid cancer	0.000191	0.00127	CcSEcCtD
Haloperidol—Thrombocytopenia—Epirubicin—thyroid cancer	0.00019	0.00127	CcSEcCtD
Haloperidol—Hypertension—Doxorubicin—thyroid cancer	0.00019	0.00127	CcSEcCtD
Haloperidol—Tachycardia—Epirubicin—thyroid cancer	0.00019	0.00126	CcSEcCtD
Haloperidol—Skin disorder—Epirubicin—thyroid cancer	0.000189	0.00126	CcSEcCtD
Haloperidol—Hyperhidrosis—Epirubicin—thyroid cancer	0.000188	0.00125	CcSEcCtD
Haloperidol—Anxiety—Doxorubicin—thyroid cancer	0.000187	0.00125	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000186	0.00124	CcSEcCtD
Haloperidol—Anorexia—Epirubicin—thyroid cancer	0.000185	0.00123	CcSEcCtD
Haloperidol—Dry mouth—Doxorubicin—thyroid cancer	0.000184	0.00122	CcSEcCtD
Haloperidol—Hypotension—Epirubicin—thyroid cancer	0.000182	0.00121	CcSEcCtD
Haloperidol—Confusional state—Doxorubicin—thyroid cancer	0.000181	0.00121	CcSEcCtD
Haloperidol—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00018	0.0012	CcSEcCtD
Haloperidol—Oedema—Doxorubicin—thyroid cancer	0.00018	0.0012	CcSEcCtD
Haloperidol—ABCB1—head—thyroid cancer	0.000177	0.00698	CbGeAlD
Haloperidol—Nervous system disorder—Doxorubicin—thyroid cancer	0.000176	0.00117	CcSEcCtD
Haloperidol—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000176	0.00117	CcSEcCtD
Haloperidol—Insomnia—Epirubicin—thyroid cancer	0.000176	0.00117	CcSEcCtD
Haloperidol—Tachycardia—Doxorubicin—thyroid cancer	0.000176	0.00117	CcSEcCtD
Haloperidol—Skin disorder—Doxorubicin—thyroid cancer	0.000175	0.00116	CcSEcCtD
Haloperidol—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000174	0.00116	CcSEcCtD
Haloperidol—Dyspnoea—Epirubicin—thyroid cancer	0.000173	0.00115	CcSEcCtD
Haloperidol—Somnolence—Epirubicin—thyroid cancer	0.000173	0.00115	CcSEcCtD
Haloperidol—Anorexia—Doxorubicin—thyroid cancer	0.000172	0.00114	CcSEcCtD
Haloperidol—Dyspepsia—Epirubicin—thyroid cancer	0.000171	0.00114	CcSEcCtD
Haloperidol—Decreased appetite—Epirubicin—thyroid cancer	0.000169	0.00113	CcSEcCtD
Haloperidol—Hypotension—Doxorubicin—thyroid cancer	0.000168	0.00112	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000168	0.00112	CcSEcCtD
Haloperidol—Constipation—Epirubicin—thyroid cancer	0.000166	0.00111	CcSEcCtD
Haloperidol—Insomnia—Doxorubicin—thyroid cancer	0.000163	0.00108	CcSEcCtD
Haloperidol—Dyspnoea—Doxorubicin—thyroid cancer	0.00016	0.00107	CcSEcCtD
Haloperidol—Feeling abnormal—Epirubicin—thyroid cancer	0.00016	0.00107	CcSEcCtD
Haloperidol—Somnolence—Doxorubicin—thyroid cancer	0.00016	0.00106	CcSEcCtD
Haloperidol—Dyspepsia—Doxorubicin—thyroid cancer	0.000158	0.00105	CcSEcCtD
Haloperidol—Decreased appetite—Doxorubicin—thyroid cancer	0.000156	0.00104	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000155	0.00103	CcSEcCtD
Haloperidol—Urticaria—Epirubicin—thyroid cancer	0.000154	0.00103	CcSEcCtD
Haloperidol—Constipation—Doxorubicin—thyroid cancer	0.000154	0.00102	CcSEcCtD
Haloperidol—Body temperature increased—Epirubicin—thyroid cancer	0.000154	0.00102	CcSEcCtD
Haloperidol—Feeling abnormal—Doxorubicin—thyroid cancer	0.000148	0.000987	CcSEcCtD
Haloperidol—Hypersensitivity—Epirubicin—thyroid cancer	0.000143	0.000954	CcSEcCtD
Haloperidol—Urticaria—Doxorubicin—thyroid cancer	0.000143	0.000951	CcSEcCtD
Haloperidol—Body temperature increased—Doxorubicin—thyroid cancer	0.000142	0.000947	CcSEcCtD
Haloperidol—Pruritus—Epirubicin—thyroid cancer	0.000138	0.000916	CcSEcCtD
Haloperidol—Diarrhoea—Epirubicin—thyroid cancer	0.000133	0.000886	CcSEcCtD
Haloperidol—Hypersensitivity—Doxorubicin—thyroid cancer	0.000133	0.000882	CcSEcCtD
Haloperidol—Dizziness—Epirubicin—thyroid cancer	0.000129	0.000856	CcSEcCtD
Haloperidol—Pruritus—Doxorubicin—thyroid cancer	0.000127	0.000847	CcSEcCtD
Haloperidol—ABCB1—lymph node—thyroid cancer	0.000124	0.00489	CbGeAlD
Haloperidol—Vomiting—Epirubicin—thyroid cancer	0.000124	0.000823	CcSEcCtD
Haloperidol—Diarrhoea—Doxorubicin—thyroid cancer	0.000123	0.000819	CcSEcCtD
Haloperidol—Rash—Epirubicin—thyroid cancer	0.000123	0.000816	CcSEcCtD
Haloperidol—Dermatitis—Epirubicin—thyroid cancer	0.000122	0.000815	CcSEcCtD
Haloperidol—Headache—Epirubicin—thyroid cancer	0.000122	0.000811	CcSEcCtD
Haloperidol—Dizziness—Doxorubicin—thyroid cancer	0.000119	0.000792	CcSEcCtD
Haloperidol—Nausea—Epirubicin—thyroid cancer	0.000116	0.000769	CcSEcCtD
Haloperidol—Vomiting—Doxorubicin—thyroid cancer	0.000114	0.000762	CcSEcCtD
Haloperidol—Rash—Doxorubicin—thyroid cancer	0.000113	0.000755	CcSEcCtD
Haloperidol—Dermatitis—Doxorubicin—thyroid cancer	0.000113	0.000754	CcSEcCtD
Haloperidol—Headache—Doxorubicin—thyroid cancer	0.000113	0.00075	CcSEcCtD
Haloperidol—Nausea—Doxorubicin—thyroid cancer	0.000107	0.000711	CcSEcCtD
Haloperidol—CYP1A1—Metabolism—TPR—thyroid cancer	2.24e-05	0.000288	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MEN1—thyroid cancer	2.24e-05	0.000287	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MEN1—thyroid cancer	2.23e-05	0.000287	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PRKAR1A—thyroid cancer	2.21e-05	0.000283	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CDK1—thyroid cancer	2.17e-05	0.000279	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CDK1—thyroid cancer	2.14e-05	0.000275	CbGpPWpGaD
Haloperidol—EBP—Metabolism—AKT1—thyroid cancer	2.07e-05	0.000266	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—RXRA—thyroid cancer	2.07e-05	0.000265	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PTCH1—thyroid cancer	2.06e-05	0.000264	CbGpPWpGaD
Haloperidol—CBR1—Metabolism—AKT1—thyroid cancer	2.04e-05	0.000262	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PTCH1—thyroid cancer	2.02e-05	0.00026	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PTCH1—thyroid cancer	2.02e-05	0.000259	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.02e-05	0.000259	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	2.01e-05	0.000259	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—NRG1—thyroid cancer	2.01e-05	0.000258	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2e-05	0.000257	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—NRG1—thyroid cancer	1.97e-05	0.000252	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—NRG1—thyroid cancer	1.94e-05	0.000248	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—HPGD—thyroid cancer	1.92e-05	0.000247	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SST—thyroid cancer	1.88e-05	0.000241	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SST—thyroid cancer	1.85e-05	0.000238	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—NRG1—thyroid cancer	1.85e-05	0.000237	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SST—thyroid cancer	1.85e-05	0.000237	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—TPR—thyroid cancer	1.83e-05	0.000235	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CALCA—thyroid cancer	1.81e-05	0.000232	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	1.81e-05	0.000232	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TERT—thyroid cancer	1.8e-05	0.000231	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—TPR—thyroid cancer	1.79e-05	0.00023	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	1.79e-05	0.00023	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CALCA—thyroid cancer	1.78e-05	0.000229	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CALCA—thyroid cancer	1.78e-05	0.000228	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—SLC5A5—thyroid cancer	1.78e-05	0.000228	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TERT—thyroid cancer	1.77e-05	0.000227	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PRKAR1A—thyroid cancer	1.76e-05	0.000226	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—NRG1—thyroid cancer	1.74e-05	0.000224	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TERT—thyroid cancer	1.74e-05	0.000223	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—HIF1A—thyroid cancer	1.73e-05	0.000221	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—NRG1—thyroid cancer	1.72e-05	0.000221	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—HIF1A—thyroid cancer	1.69e-05	0.000217	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—TPR—thyroid cancer	1.69e-05	0.000217	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—SLC5A5—thyroid cancer	1.68e-05	0.000215	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—TPR—thyroid cancer	1.67e-05	0.000215	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—HIF1A—thyroid cancer	1.66e-05	0.000213	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	1.66e-05	0.000213	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TERT—thyroid cancer	1.66e-05	0.000213	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	1.65e-05	0.000211	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CDK1—thyroid cancer	1.64e-05	0.00021	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.64e-05	0.00021	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CDK1—thyroid cancer	1.61e-05	0.000207	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CDK1—thyroid cancer	1.61e-05	0.000207	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—HIF1A—thyroid cancer	1.59e-05	0.000204	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.57e-05	0.000202	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TERT—thyroid cancer	1.56e-05	0.000201	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PPARG—thyroid cancer	1.55e-05	0.000199	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TERT—thyroid cancer	1.54e-05	0.000198	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—NRAS—thyroid cancer	1.52e-05	0.000195	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.51e-05	0.000194	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—HIF1A—thyroid cancer	1.5e-05	0.000192	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—RXRA—thyroid cancer	1.49e-05	0.000192	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.49e-05	0.000191	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—NRAS—thyroid cancer	1.49e-05	0.000191	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—HIF1A—thyroid cancer	1.48e-05	0.000189	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—NRAS—thyroid cancer	1.46e-05	0.000188	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—TPR—thyroid cancer	1.43e-05	0.000183	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—BRAF—thyroid cancer	1.43e-05	0.000183	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—RXRA—thyroid cancer	1.41e-05	0.000181	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	1.41e-05	0.00018	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—BRAF—thyroid cancer	1.4e-05	0.00018	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—NRAS—thyroid cancer	1.4e-05	0.000179	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—BRAF—thyroid cancer	1.38e-05	0.000177	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—SLC5A5—thyroid cancer	1.37e-05	0.000176	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.37e-05	0.000176	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.34e-05	0.000172	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—NRAS—thyroid cancer	1.32e-05	0.000169	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—NRG1—thyroid cancer	1.32e-05	0.000169	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—BRAF—thyroid cancer	1.31e-05	0.000169	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—KRAS—thyroid cancer	1.31e-05	0.000168	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PPARG—thyroid cancer	1.3e-05	0.000167	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—NRAS—thyroid cancer	1.3e-05	0.000167	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—NRG1—thyroid cancer	1.29e-05	0.000166	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—NRG1—thyroid cancer	1.29e-05	0.000166	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.29e-05	0.000165	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—KRAS—thyroid cancer	1.28e-05	0.000164	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.27e-05	0.000164	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—SLC5A5—thyroid cancer	1.26e-05	0.000162	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—KRAS—thyroid cancer	1.26e-05	0.000162	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.25e-05	0.000161	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—BRAF—thyroid cancer	1.24e-05	0.000159	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—BRAF—thyroid cancer	1.22e-05	0.000157	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PTGS2—thyroid cancer	1.22e-05	0.000156	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—KRAS—thyroid cancer	1.2e-05	0.000154	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TERT—thyroid cancer	1.18e-05	0.000152	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.17e-05	0.000151	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TERT—thyroid cancer	1.16e-05	0.000149	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TERT—thyroid cancer	1.16e-05	0.000149	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—RXRA—thyroid cancer	1.15e-05	0.000148	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—KRAS—thyroid cancer	1.13e-05	0.000146	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—HIF1A—thyroid cancer	1.13e-05	0.000145	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—RXRA—thyroid cancer	1.13e-05	0.000145	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.12e-05	0.000144	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—KRAS—thyroid cancer	1.12e-05	0.000144	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—HRAS—thyroid cancer	1.11e-05	0.000143	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—HIF1A—thyroid cancer	1.11e-05	0.000143	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—HIF1A—thyroid cancer	1.11e-05	0.000142	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—TPR—thyroid cancer	1.1e-05	0.000142	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—HRAS—thyroid cancer	1.09e-05	0.00014	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.09e-05	0.000139	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—AKT1—thyroid cancer	1.08e-05	0.000139	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—HRAS—thyroid cancer	1.07e-05	0.000137	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—SLC5A5—thyroid cancer	1.07e-05	0.000137	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PTEN—thyroid cancer	1.06e-05	0.000136	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—RXRA—thyroid cancer	1.06e-05	0.000136	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—AKT1—thyroid cancer	1.06e-05	0.000136	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—RXRA—thyroid cancer	1.05e-05	0.000135	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CCND1—thyroid cancer	1.04e-05	0.000134	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—AKT1—thyroid cancer	1.04e-05	0.000134	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PTGS2—thyroid cancer	1.03e-05	0.000132	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.02e-05	0.000131	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—HRAS—thyroid cancer	1.02e-05	0.000131	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CCND1—thyroid cancer	1.02e-05	0.000131	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—PTEN—thyroid cancer	1.01e-05	0.000129	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CCND1—thyroid cancer	1e-05	0.000129	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1e-05	0.000129	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—NRAS—thyroid cancer	9.95e-06	0.000128	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—AKT1—thyroid cancer	9.94e-06	0.000128	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PTEN—thyroid cancer	9.85e-06	0.000126	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—AKT1—thyroid cancer	9.82e-06	0.000126	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—NRAS—thyroid cancer	9.79e-06	0.000126	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—NRAS—thyroid cancer	9.77e-06	0.000125	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PTEN—thyroid cancer	9.7e-06	0.000124	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—HRAS—thyroid cancer	9.64e-06	0.000124	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—AKT1—thyroid cancer	9.61e-06	0.000123	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CCND1—thyroid cancer	9.59e-06	0.000123	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—HRAS—thyroid cancer	9.52e-06	0.000122	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—AKT1—thyroid cancer	9.46e-06	0.000121	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PPARG—thyroid cancer	9.42e-06	0.000121	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—AKT1—thyroid cancer	9.38e-06	0.00012	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—BRAF—thyroid cancer	9.36e-06	0.00012	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PTEN—thyroid cancer	9.26e-06	0.000119	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—AKT1—thyroid cancer	9.25e-06	0.000119	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—BRAF—thyroid cancer	9.21e-06	0.000118	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—BRAF—thyroid cancer	9.19e-06	0.000118	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CCND1—thyroid cancer	9.04e-06	0.000116	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—AKT1—thyroid cancer	9.03e-06	0.000116	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—RXRA—thyroid cancer	8.99e-06	0.000115	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—NRAS—thyroid cancer	8.98e-06	0.000115	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PTEN—thyroid cancer	8.94e-06	0.000115	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CCND1—thyroid cancer	8.92e-06	0.000115	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PPARG—thyroid cancer	8.9e-06	0.000114	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—NRAS—thyroid cancer	8.79e-06	0.000113	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	8.75e-06	0.000112	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PTEN—thyroid cancer	8.73e-06	0.000112	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—NRAS—thyroid cancer	8.65e-06	0.000111	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PTEN—thyroid cancer	8.61e-06	0.000111	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—KRAS—thyroid cancer	8.57e-06	0.00011	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—AKT1—thyroid cancer	8.52e-06	0.000109	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—KRAS—thyroid cancer	8.43e-06	0.000108	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—KRAS—thyroid cancer	8.41e-06	0.000108	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—AKT1—thyroid cancer	8.4e-06	0.000108	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—SLC5A5—thyroid cancer	8.26e-06	0.000106	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—NRAS—thyroid cancer	8.26e-06	0.000106	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—NRAS—thyroid cancer	7.79e-06	9.99e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—KRAS—thyroid cancer	7.73e-06	9.92e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—NRAS—thyroid cancer	7.68e-06	9.86e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—KRAS—thyroid cancer	7.57e-06	9.71e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—KRAS—thyroid cancer	7.45e-06	9.55e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTGS2—thyroid cancer	7.41e-06	9.51e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PPARG—thyroid cancer	7.29e-06	9.35e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—HRAS—thyroid cancer	7.28e-06	9.34e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—HRAS—thyroid cancer	7.17e-06	9.19e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—HRAS—thyroid cancer	7.15e-06	9.17e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PPARG—thyroid cancer	7.11e-06	9.13e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—KRAS—thyroid cancer	7.11e-06	9.12e-05	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—AKT1—thyroid cancer	7.08e-06	9.09e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTGS2—thyroid cancer	7e-06	8.99e-05	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—AKT1—thyroid cancer	6.97e-06	8.94e-05	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—AKT1—thyroid cancer	6.95e-06	8.92e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—RXRA—thyroid cancer	6.94e-06	8.9e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TP53—thyroid cancer	6.87e-06	8.81e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCND1—thyroid cancer	6.83e-06	8.76e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TP53—thyroid cancer	6.73e-06	8.63e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCND1—thyroid cancer	6.72e-06	8.62e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCND1—thyroid cancer	6.7e-06	8.6e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—KRAS—thyroid cancer	6.7e-06	8.6e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PPARG—thyroid cancer	6.7e-06	8.6e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PPARG—thyroid cancer	6.64e-06	8.53e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TP53—thyroid cancer	6.62e-06	8.49e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—KRAS—thyroid cancer	6.61e-06	8.49e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PTEN—thyroid cancer	6.59e-06	8.46e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—HRAS—thyroid cancer	6.57e-06	8.43e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PTEN—thyroid cancer	6.48e-06	8.32e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PTEN—thyroid cancer	6.47e-06	8.3e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTEN—thyroid cancer	6.47e-06	8.3e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—HRAS—thyroid cancer	6.43e-06	8.25e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—AKT1—thyroid cancer	6.43e-06	8.25e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—HRAS—thyroid cancer	6.33e-06	8.12e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—AKT1—thyroid cancer	6.33e-06	8.12e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TP53—thyroid cancer	6.32e-06	8.11e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—AKT1—thyroid cancer	6.31e-06	8.1e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—AKT1—thyroid cancer	6.13e-06	7.87e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTEN—thyroid cancer	6.11e-06	7.84e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—HRAS—thyroid cancer	6.04e-06	7.75e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TP53—thyroid cancer	5.96e-06	7.64e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—NRAS—thyroid cancer	5.88e-06	7.55e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TP53—thyroid cancer	5.88e-06	7.54e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—AKT1—thyroid cancer	5.8e-06	7.44e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—NRAS—thyroid cancer	5.79e-06	7.42e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—NRAS—thyroid cancer	5.77e-06	7.41e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTGS2—thyroid cancer	5.73e-06	7.36e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—HRAS—thyroid cancer	5.7e-06	7.31e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—AKT1—thyroid cancer	5.68e-06	7.29e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PPARG—thyroid cancer	5.68e-06	7.29e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—HRAS—thyroid cancer	5.62e-06	7.21e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTGS2—thyroid cancer	5.59e-06	7.18e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—AKT1—thyroid cancer	5.59e-06	7.17e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—AKT1—thyroid cancer	5.33e-06	6.85e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTGS2—thyroid cancer	5.27e-06	6.76e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTGS2—thyroid cancer	5.23e-06	6.71e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—AKT1—thyroid cancer	5.16e-06	6.61e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KRAS—thyroid cancer	5.06e-06	6.49e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—AKT1—thyroid cancer	5.03e-06	6.46e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTEN—thyroid cancer	5e-06	6.41e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KRAS—thyroid cancer	4.98e-06	6.39e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KRAS—thyroid cancer	4.97e-06	6.38e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—AKT1—thyroid cancer	4.96e-06	6.37e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTEN—thyroid cancer	4.88e-06	6.26e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTEN—thyroid cancer	4.6e-06	5.9e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTEN—thyroid cancer	4.56e-06	5.85e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TP53—thyroid cancer	4.5e-06	5.77e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTGS2—thyroid cancer	4.47e-06	5.73e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TP53—thyroid cancer	4.43e-06	5.68e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TP53—thyroid cancer	4.42e-06	5.67e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PPARG—thyroid cancer	4.38e-06	5.62e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—HRAS—thyroid cancer	4.3e-06	5.52e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—HRAS—thyroid cancer	4.23e-06	5.43e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—HRAS—thyroid cancer	4.22e-06	5.42e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTEN—thyroid cancer	3.9e-06	5e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—AKT1—thyroid cancer	3.8e-06	4.87e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—AKT1—thyroid cancer	3.74e-06	4.8e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—AKT1—thyroid cancer	3.73e-06	4.79e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—AKT1—thyroid cancer	3.73e-06	4.78e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—AKT1—thyroid cancer	3.52e-06	4.52e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTGS2—thyroid cancer	3.45e-06	4.42e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTEN—thyroid cancer	3.01e-06	3.86e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—AKT1—thyroid cancer	2.88e-06	3.7e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—AKT1—thyroid cancer	2.81e-06	3.61e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—AKT1—thyroid cancer	2.65e-06	3.4e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—AKT1—thyroid cancer	2.63e-06	3.37e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—AKT1—thyroid cancer	2.24e-06	2.88e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—AKT1—thyroid cancer	1.73e-06	2.22e-05	CbGpPWpGaD
